HighVista Strategies LLC

BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$380.9M2026 Q3
Positions136
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.27.2%

HighVista Strategies LLC reported 136 positions worth $380.9M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: DBC (9.0%). Biggest move: new buy GMAB ($8.1M).

10 / 136 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 DBCInvesco DB Commodity$34.2M8.97%1,057,238———
▸ 2 RVMDRevolution Medicines$9.4M2.47%45,897——-18.7%
▸ 3 ABVXAbivax S.A.$8.6M2.26%87,057———
▸ 4 PCVXVaxcyte$8.1M2.12%142,107——+8.3%
▸ 5 GMABGenmab A/S$8.1M2.12%226,098———
▸ 6 RLAYRelay Therapeutics$7.4M1.94%409,325——-4.3%
▸ 7 TNGXTango Therapeutics$7.2M1.89%287,769——-3.1%
▸ 8 TARSTarsus Pharmaceuticals$7.1M1.87%90,432——+2.1%
▸ 9 IMVTImmunovant$7.0M1.83%205,954——-1.5%
▸ 10 COGTCogent Biosciences$6.7M1.77%210,055——-10.8%

Pro Feature

The remaining 126 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does HighVista Strategies LLC hold as of Q3 2026?

HighVista Strategies LLC reported 136 positions worth $380.9M in its Q3 2026 13F filing. Largest positions: DBC (9.0%), RVMD (2.5%), ABVX (2.3%), PCVX (2.1%) and GMAB (2.1%).

What did HighVista Strategies LLC buy in Q3 2026?

New positions: GMAB, MANE, CTNM, UNP and UAL (24 in all). Added to: EWTX, META, VRDN, TLN and MBX (48 in all).

What did HighVista Strategies LLC sell in Q3 2026?

Reduced: AMLX, PRAX, DFTX, RVMD and CYTK (63 in all). Sold out entirely: ALMS, MLYS, EYPT, RBC and RKT (35 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.